Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_assertion description "[We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_assertion evidence source_evidence_literature NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_assertion SIO_000772 12640257 NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_assertion wasDerivedFrom befree-20140225 NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_assertion wasGeneratedBy ECO_0000203 NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.
- befree-20140225 importedOn "2014-02-25" NP180223.RABgb4tzSe2pYAFncmCecaUs1_uEbdLVOthBXsNiaioDE130_provenance.